Sildenafil (Generic) vs Vardenafil (Levitra/Staxyn): Comparing the Two and the Rationale and Risk of Combining Them

How Sildenafil and Vardenafil Work

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in penile smooth muscle. Sexual stimulation triggers nitric oxide release, which raises cGMP and causes smooth-muscle relaxation in the corpus cavernosum. PDE5 inhibitors preserve that cGMP signal long enough to produce and maintain an erection.

The landmark 1998 trial by Goldstein et al. Published in the New England Journal of Medicine confirmed this mechanism in 532 men with erectile dysfunction (ED), showing that sildenafil produced successful intercourse in 69% of attempts vs. 22% with placebo 1.

Why They Are Not Identical

Despite sharing the same target enzyme, sildenafil and vardenafil differ at the molecular level. Vardenafil has a higher binding affinity for PDE5 (IC50 approximately 0.7 nM) compared with sildenafil (IC50 approximately 3.9 nM), meaning vardenafil achieves equivalent PDE5 inhibition at a lower milligram dose. This tighter binding also translates to somewhat greater selectivity over PDE6, the retinal isoform responsible for the transient blue-tinge visual disturbance occasionally reported with sildenafil.

PDE5 Selectivity Profiles

Sildenafil inhibits PDE6 at concentrations not far above its PDE5 IC50, which explains why visual side effects (blue-tinge, altered light perception) appear in roughly 3% of users at the 100 mg dose, per the FDA label 2. Vardenafil's PDE6 selectivity ratio is approximately tenfold better, making visual complaints uncommon at therapeutic doses. Both drugs show weak activity against PDE11, a cardiac isoform, but the clinical significance of this remains uncertain.

Sildenafil: Dosing, Onset, and Food Effects

Sildenafil is available as generic tablets in 20 mg, 25 mg, 50 mg, and 100 mg strengths. The FDA-approved starting dose for ED is 50 mg, taken 30 to 60 minutes before activity, with a maximum of one dose per 24 hours 2.

Food Interaction Is Clinically Meaningful

A high-fat meal delays sildenafil's time to peak plasma concentration (Tmax) from roughly 60 minutes to 2 hours and reduces peak concentration (Cmax) by approximately 29%. Patients who take sildenafil after a heavy meal and then report "it didn't work" are often experiencing this pharmacokinetic delay rather than true drug failure.

Dose Titration

Physicians typically start at 50 mg and titrate to 100 mg if the response is inadequate and tolerability is confirmed. In men over 65, or those with hepatic impairment or creatinine clearance <30 mL/min, the starting dose is 25 mg. Sildenafil 20 mg three-times-daily is separately approved for pulmonary arterial hypertension (as Revatio), which is why the 20 mg tablet exists on pharmacy shelves at much lower cost per milligram.

Vardenafil (Levitra and Staxyn): Dosing, Onset, and the ODT Difference

Levitra (film-coated vardenafil) is available in 5 mg, 10 mg, and 20 mg tablets. The recommended starting dose is 10 mg, taken 25 to 60 minutes before sexual activity, once per 24 hours 3. Moderate-fat meals have minimal impact on vardenafil pharmacokinetics, giving it a practical scheduling advantage over sildenafil for men who eat normally before activity.

Staxyn Is Not a Substitute for Levitra

Staxyn is a 10 mg orally disintegrating tablet (ODT) formulation of vardenafil. Because it dissolves under the tongue and is absorbed through the buccal mucosa as well as the GI tract, its pharmacokinetic profile differs from film-coated Levitra. The FDA label explicitly states that Staxyn 10 mg ODT is not bioequivalent to Levitra 10 mg and the two should not be used interchangeably 4. Staxyn is also contraindicated in patients taking certain HIV protease inhibitors (ritonavir, indinavir) due to CYP3A4 inhibition.

QT-Interval Consideration

Vardenafil produces mild QTc prolongation at supratherapeutic doses. A thorough QT study showed a mean QTcF increase of 8 ms at the 10 mg dose and 10 ms at 80 mg. This is clinically relevant for men taking class IA antiarrhythmics (quinidine, procainamide) or class III agents (amiodarone, sotalol), where combination is contraindicated 3. Sildenafil does not carry a significant QT-prolongation signal at therapeutic doses.

Head-to-Head Efficacy: What the Trials Show

Direct comparative data is limited because most trials compared each drug to placebo rather than to each other.

The Porst 2003 Trial

Porst et al. (2003) conducted one of the first head-to-head comparison studies, enrolling men with ED across sildenafil, vardenafil, and placebo arms. Vardenafil 20 mg and sildenafil 50 mg produced statistically similar improvements in the International Index of Erectile Function (IIEF) erectile function domain score, but vardenafil showed a numerically faster onset in a subset analysis. The authors noted that "both compounds were effective and well tolerated, and patient preference varied," underscoring that drug selection is often driven by tolerability and lifestyle factors rather than raw efficacy 5.

Pooled Response Rates

Across registration trials, approximately 74-82% of men with mild-to-moderate ED achieve successful intercourse with sildenafil 50-100 mg 1. Vardenafil phase III trials reported successful intercourse rates of 75-80% with 10-20 mg 3. In men with diabetes-associated ED (a population with lower baseline response), sildenafil 100 mg produced successful intercourse in 57% of attempts vs. 10% for placebo in Rendell et al. (1999) (N=268) 6.

What Determines a Better Response

Etiology of ED matters more than drug choice for most men. Psychogenic ED responds well to either agent at standard doses. Vasculogenic ED, which is common in men with diabetes, hypertension, or cardiovascular disease, tends to need higher doses and benefit from consistent, scheduled dosing to restore endothelial function over time. Neither drug significantly outperforms the other across this population when doses are equipotent-adjusted.

Side-Effect Comparison

Both drugs share a class-wide side-effect profile driven by off-target vasodilation. The frequency differences below come from respective FDA labels and meta-analyses.

| Side Effect | Sildenafil (50-100 mg) | Vardenafil (10-20 mg) | |---|---|---| | Headache | 16% | 15% | | Flushing | 10% | 11% | | Nasal congestion | 4% | 9% | | Dyspepsia | 7% | 4% | | Visual disturbances | 3% | <1% | | Back pain | <2% | 2% | | QT prolongation | Not significant | Mild (8 ms at 10 mg) |

Vasodilatory Side Effects

Headache and flushing are the most reported complaints for both agents. These result from systemic nitric-oxide-mediated vasodilation beyond the corpus cavernosum. Taking either drug with alcohol amplifies this risk because ethanol is itself a vasodilator. Men who report intolerable flushing on sildenafil 100 mg may tolerate vardenafil 10 mg better, though this is individual variation rather than a pharmacological guarantee.

The Nasal Congestion Difference

Nasal congestion appears roughly twice as often with vardenafil (9%) as with sildenafil (4%) in label-reported data. This is not dangerous but can be a reason men prefer sildenafil. Conversely, the lower rate of visual disturbance with vardenafil matters for men who drive or operate equipment shortly after a dose.

Combining Sildenafil and Vardenafil: The Rationale Clinicians Encounter

Some patients ask whether taking both drugs together might work better when one alone has not produced a satisfactory erection. The rationale sounds logical on the surface. Two PDE5 inhibitors should block more PDE5 than one. In practice, this reasoning is pharmacologically flawed and clinically dangerous.

Why the Rationale Fails

At standard doses, both sildenafil (50-100 mg) and vardenafil (10-20 mg) already produce near-maximal PDE5 inhibition in penile tissue during sexual stimulation. The limiting factor for men who get a partial response is not residual PDE5 activity. The limit is usually inadequate nitric-oxide release from impaired endothelium, insufficient sexual stimulation, anxiety, or an underlying vascular or hormonal cause that a PDE5 inhibitor alone cannot fix. Adding a second PDE5 inhibitor does not address any of these bottlenecks.

The Hemodynamic Risk

Both sildenafil and vardenafil lower systemic blood pressure. Sildenafil 100 mg produces a mean maximum decrease in systolic blood pressure of approximately 8.4 mmHg in healthy volunteers 2. Vardenafil 20 mg produces a mean maximum decrease of approximately 6.9 mmHg 3. These effects are additive, not counterbalancing, when both agents are present in circulation simultaneously. Clinically, this combination could precipitate symptomatic hypotension (dizziness, syncope, falls) or, in men with underlying ischemic heart disease, myocardial ischemia triggered by a sudden drop in diastolic filling pressure.

Nitrate Interaction Makes Combination Even More Dangerous

If a patient is also taking any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite), stacking two PDE5 inhibitors on top dramatically amplifies the risk of severe, potentially fatal hypotension. The American College of Cardiology/American Heart Association guidelines on stable ischemic heart disease rate the PDE5-inhibitor-nitrate combination as a Class III harm recommendation 7. Adding a second PDE5 inhibitor to a patient already on a nitrate extends that danger window by hours.

Clinical Framework: When a Second PDE5 Inhibitor Is Appropriate

The correct clinical move when one PDE5 inhibitor fails is not combination therapy. Instead, the stepwise approach is:

1. Confirm the diagnosis. Check serum testosterone (total and free), fasting glucose, HbA1c, lipid panel, and blood pressure. Low testosterone responds to TRT or clomiphene, not higher PDE5 inhibitor doses.
2. Optimize the current drug first. Ensure the patient is taking the maximum approved dose (sildenafil 100 mg or vardenafil 20 mg), on an empty stomach if applicable, with adequate stimulation, and has given the drug 8-10 attempts before declaring failure.
3. Switch to a different PDE5 inhibitor, not stack. Tadalafil 5 mg once-daily may work for men who fail on-demand dosing by maintaining continuous low-level PDE5 inhibition and supporting endothelial repair. Avanafil may suit men who need rapid onset (15 minutes) without food restriction.
4. Consider intracavernosal alprostadil if two different PDE5 inhibitors both fail at maximum dose, as per AUA erectile dysfunction guidelines 8.
5. Refer to urology or sexual medicine if the response remains inadequate after two optimized PDE5 inhibitor trials.

No credentialed guideline from the AUA, EAU, or ACC/AHA endorses combining two PDE5 inhibitors. The combination is not a recognized off-label use with any clinical evidence base.

Switching from Sildenafil to Vardenafil: When It Makes Sense

Switching is clinically reasonable and safe when done correctly. It is not the same as combining. The patient stops one agent entirely before starting the other.

Reasons to Switch

A patient may benefit from switching to vardenafil if they experience:

• Persistent visual disturbances on sildenafil (vardenafil's better PDE6 selectivity may resolve this)
• Significant food-related dosing inconvenience (vardenafil is less affected by moderate fat content)
• Preference for the Staxyn ODT formulation for discreet, no-water dosing
• Dyspepsia on sildenafil (vardenafil's lower PDE11 activity may reduce GI complaints in some patients)

Reasons to Stay with Sildenafil

Sildenafil makes more sense for patients who:

• Need the lowest cost option, since generic sildenafil is widely available at $1-3 per tablet at major pharmacies
• Have a cardiac history requiring QT caution (vardenafil's mild QT effect is relevant here)
• Already use the 20 mg pulmonary hypertension dose for off-label ED and are tolerating it well
• Have tried vardenafil previously without benefit

How to Switch Safely

Allow at least five half-lives (approximately 24 hours) after the last sildenafil dose before taking vardenafil. Start vardenafil at 10 mg regardless of what sildenafil dose was being used. Titrate up to 20 mg only if 10 mg is ineffective and well tolerated after at least 4-6 attempts. Men over 65 should begin at 5 mg. Men taking moderate CYP3A4 inhibitors (erythromycin, ketoconazole 200 mg daily) should cap vardenafil at 5 mg per the FDA label 3.

Special Populations and Drug Interactions

Men with Cardiovascular Disease

The Princeton III Consensus Statement recommends a structured cardiovascular risk assessment before prescribing any PDE5 inhibitor 9. Men in the high-risk category (unstable angina, recent MI within 2 weeks, uncontrolled hypertension above 170/110 mmHg, NYHA class IV heart failure) should not receive either drug until stabilized. For men in the intermediate-risk category, an exercise stress test or cardiology referral is appropriate before prescribing.

Men with Diabetes

Diabetes-associated ED is common. The IIEF-5 score is <21 in approximately 50% of diabetic men over 50 per CDC data 10. Both sildenafil and vardenafil are effective in this population, though response rates are lower than in non-diabetic men. Vardenafil 10 mg and 20 mg showed significant IIEF-EF domain score improvements in a trial of 452 diabetic men (Goldstein et al. 2003), with 10 mg producing a mean domain score increase of 6.1 points vs. 1.1 for placebo 11.

Alpha-Blocker Co-Administration

Both drugs can potentiate the blood-pressure-lowering effects of alpha-blockers (tamsulosin, doxazosin). The FDA labels for both agents include a warning about this interaction. For sildenafil, the interaction is most significant with non-selective alpha-blockers like doxazosin. For vardenafil, tamsulosin 0.4 mg co-administration produced no significant additional blood pressure reduction in formal pharmacodynamic studies, making tamsulosin the preferred alpha-blocker when concurrent PDE5 inhibitor use is needed in men with benign prostatic hyperplasia.

Cost and Access Considerations

Generic sildenafil became widely available in the United States after Pfizer's patent expiration in 2017 and now costs $1 to $3 per tablet at major retail pharmacies with discount programs. Generic vardenafil became available in the US around 2018, but market penetration remains lower, and retail prices commonly run $8 to $15 per tablet without manufacturer coupons. Staxyn ODT carries a brand premium and is not available generically.

For patients without insurance covering ED medications, this cost differential is a major practical factor. Sildenafil's price point makes daily low-dose trials (25 mg daily as an off-label endothelial conditioning strategy) financially feasible in a way that vardenafil is not for most patients.

Summary Comparison Table

| Feature | Sildenafil (Generic) | Vardenafil (Levitra/Staxyn) | |---|---|---| | FDA-approved dose range | 25-100 mg | 5-20 mg (Levitra); 10 mg ODT (Staxyn) | | Onset | 30-60 min | 25-60 min | | Duration of action | 4-6 hours | 4-6 hours | | Half-life | 3-5 hours | 4-5 hours | | Food interaction | High-fat meal delays significantly | Minimal with moderate meals | | PDE6 selectivity | Moderate | Higher (fewer visual side effects) | | QT prolongation | Negligible | Mild (8 ms at 10 mg) | | Visual side effects | ~3% at 100 mg | <1% | | Generic availability | Yes, widely available | Yes, limited availability | | Approximate cost (generic) | $1-3 per tablet | $8-15 per tablet | | Combining both | Contraindicated | Contraindicated |